0,1
"6.2.2.6	
Summary of evidence and guidelines for radical inguinal lymph node dissection in cN1-2 disease",
Recommendations,Strength rating
"In patients with cN1 disease offer either ipsilateral:
• 
fascial-sparing inguinal lymph node dissection (ILND) 
• 
open radical ILND; sparing the saphenous vein, if possible",Strong
"In patients with cN2 disease offer ipsilateral open radical ILND; sparing the saphenous vein, 
if possible.",Strong
Offer minimally-invasive ILND to patients with cN1–2 disease only as part of a clinical trial.,Strong
"Offer neoadjuvant chemotherapy as an alternative approach to upfront surgery to selected 
patients with bulky mobile inguinal nodes or bilateral disease (cN2) who are candidates for 
cisplatin and taxane-based chemotherapy (see Section 6.4.1).",Weak
"Complete surgical inguinal and pelvic nodal management within three months of diagnosis 
(unless the patient has undergone prior neoadjuvant chemotherapy).",Weak
